rent-now

Rent More, Save More! Use code: ECRENTAL

5% off 1 book, 7% off 2 books, 10% off 3+ books

9780470281765

Compatibility of Pharmaceutical Solutions and Contact Materials Safety Assessments of Extractables and Leachables for Pharmaceutical Products

by
  • ISBN13:

    9780470281765

  • ISBN10:

    0470281766

  • Edition: 1st
  • Format: Hardcover
  • Copyright: 2009-06-02
  • Publisher: Wiley-Interscience
  • Purchase Benefits
List Price: $167.41 Save up to $0.17
  • Buy New
    $167.24
    Add to Cart Free Shipping Icon Free Shipping

    PRINT ON DEMAND: 2-4 WEEKS. THIS ITEM CANNOT BE CANCELLED OR RETURNED.

Summary

This book specifically addresses the safety aspects of compatibility for drugs and their delivery devices and containers. The author deals with issues such as how the leachables impact safety of a therapeutic product and, more importantly, how one ascertains the magnitude of the impact. The book examines the strategies and tactics for performing safety assessments for leachables and extractables and establishes the means for interpreting the results obtained from such assessments. It helps the pharmaceutical industry unify methodology for assessing leachables and extractables safety of drug packaging.

Author Biography

Dennis Jenke is Principal Scientist in the Technology Resources Division of the Baxter Healthcare Corporation. He works with a team of analytical chemistry professionals in areas including the assessment of material/product compatibility, specifically with respect to leachables/extractables and product ingredient binding. He has published extensively in the areas of analytical chemistry, environmental science, and material/solution compatibility; serves as an expert reviewer for numerous pharmaceutical and analytical journals; is a frequently invited speaker in the general areas of analytical chemistry and material/solution compatibility; and is currently an active participant in ongoing collaborative activities designed to establish harmonized best demonstrated practices for extractables/leachables assessment.

Table of Contents

Preface and Acknowledgmentsp. xv
General Conceptsp. 1
Introductionp. 3
General Discussionp. 3
Key Definitionsp. 6
The Interacting Partiesp. 6
Extractables versus Leachablesp. 7
Regulatory Perspectives for Performing Compatibility and/or Safety Assessmentsp. 13
The U.S. Food and Drug Administration Guidance for Industry: Container Closure Systems for Packaging Human Drugs and Biologicsp. 14
European Medicines Agency (EMEA) Guideline on Plastic Immediate Packaging Materialsp. 15
FDA Guidance for Industry, Inhalation Productsp. 18
Medical Devicesp. 20
An Overview of Strategies for Performing Safety Assessmentsp. 21
The Generalized Strategy for Safety Assessmentsp. 22
Moving Forwardp. 24
Referencesp. 25
Nomenclature and General Conceptsp. 27
Generalp. 27
Nomenclaturep. 27
Primary Definitionsp. 28
Constituents of a Material or Constructp. 29
Classification of Extracting Mediap. 31
Classification of Extraction Strategiesp. 32
Example Extraction Conditions Applied to a Model Systemp. 39
Correlationp. 43
Factors That Influence the Linking of Extractables and Leachablesp. 44
A Hierarchy for Linkages between Extractables and Leachablesp. 44
Decisions Concerning the Required Rigor for Linkagesp. 47
Circumstances Requiring the Linking of Extractables and Leachablesp. 48
Identification and Quantitationp. 50
Risks and Risk Managementp. 55
Risk Categories Related to Biological Assessment of Medical Devicesp. 58
Risk Categories Related to Assessment of Primary Packaging and/or Container-Closure Systemsp. 58
The General Dimensions of Riskp. 64
Utilization of Risk Classification Profilesp. 68
Risk Classification in Indirect Contact Situationsp. 71
The Construct Itself as a Contributor to Riskp. 73
Referencesp. 74
Extractables, Leachables, and the Product Life Cyclep. 77
Generalp. 77
Discussion of the Components of the Master Flow Diagramp. 78
Observationsp. 83
Application of the Process Mapp. 87
Material Characterizationp. 89
Material Screening and Characterizationp. 91
Overviewp. 91
General Principlesp. 94
Compendial Compliancep. 97
United States Pharmacopeiap. 98
Japanese Pharmaceopeiap. 101
European Pharmacopeiap. 102
Compositional Characterization, General Conceptsp. 103
Compositional Characterization by Collecting Available Material Informationp. 104
Generalp. 104
Collecting Extractables Information from the Material Supplierp. 106
Compositional Characterization by Material Testing, Extractables Surveyp. 112
Extractables Survey: Extractionp. 112
Case Studies: The Influence of Extraction Medium on the Extractables Surveyp. 121
Extractables Survey: Extract Analysisp. 124
Case Study: Extractables Survey for Plastic Tubing Materialsp. 131
Case Study: Extractables Survey for an Elastomer Used in OINDPp. 136
Case Study: Extractables Survey for a Rubber Closure Used with Semisolid Drug Productsp. 137
Case Study: Extractables Survey for Filter Cartridges Used in Downstream Processing of Pharmaceuticalsp. 138
Bibliography of Analytical Methodsp. 139
Reconciliation as a Survey Toolp. 140
Case Study: TOC Reconciliation; Characterization of a Polyolefin Materialp. 141
Use of Extractables Information in Safety Assessment: Extractables Profile, Total Pool, and Total Available Poolp. 142
Extractions to Establish the Total Pool and Total Available Poolp. 143
Case Study: Total Pool Determination by Successive Extractionp. 145
Recap: Components of a Complete Extractables Assessmentp. 146
Caveats in Using Extractables Information for Safety Assessmentp. 149
Chemical Characterization: Device Perspective per ISO 10993-18p. 152
Referencesp. 154
Construct Qualificationp. 157
The Prototype Stagep. 159
General Commentsp. 159
The Simulation Studyp. 161
Generating the Simulating Extractp. 162
Simulating the Contact Parametersp. 164
Simulating the Therapeutic Productp. 166
Simulating the Exposure Parametersp. 169
Analyzing the Simulating Extractp. 171
Case Study: Modeling of the Impact of Solubilizing Agents on Leachables Accumulationp. 172
Case Study: Accumulation of Organic Leachables from Plastic Biopharmaceutical Process Containersp. 174
Case Study: Accumulation of Label-Related Leachables in a Solid Dosage Formp. 179
Case Study: Accumulation of Caprolactam Oligomers Leached from Nylon-6 Materialp. 180
Application of the Analytical Thresholdp. 181
The Preliminary Toxicological Assessmentp. 184
Case Study: Assessment of Cyclohexanone Limits for Containersp. 188
Exiting the Prototype Stagep. 188
Referencesp. 189
The Early Development Stagep. 191
General Commentsp. 191
Target Leachablesp. 192
Method Development, Evaluation, and Validationp. 194
Method Development (Optimization)p. 195
Prerequisites to Method Optimizationp. 195
Overview of the Method Optimization Processp. 197
Conduct of a Method Optimization Studyp. 200
Primary Performance Assessmentp. 201
Troubleshooting Guidep. 202
Secondary Performance Assessmentp. 204
System Suitabilityp. 205
Robustnessp. 205
Exiting Method Development-Optimizationp. 206
The Method Evaluation Processp. 206
Generalp. 206
Aspects of the Evaluation and Validation Processesp. 207
Overview of the Method Evaluation Processp. 207
Template for the Conduct of a Method Evaluation Studyp. 209
Validationp. 214
Case Study: Validation of an LC/MS Method for the Quantitation of Leachables from a Packaging Systemp. 215
Generalp. 215
Experimentalp. 216
Validation Studyp. 218
Case Study: Validation of an HPLC Method for Quantitating Stopper Leachables in a Complex Surfactant Vehiclep. 225
Generalp. 225
Validationp. 225
Exiting the Early Development Stagep. 228
Referencesp. 228
Construct Validationp. 229
Late Stage Product Developmentp. 231
General: The Migration Studyp. 231
Design of the Migration Studyp. 233
EMEA Guideline on Plastic Immediate Packaging Materialsp. 233
FDA Guidancep. 233
Optimal Design of a Migration Studyp. 234
Interpretation of the Migration Study: Toxicological Assessmentp. 238
Disaster Managementp. 238
Class A Disaster: Unusual or Unexpected Change in the Concentration of a Target Leachablep. 239
Class B Disaster: A Previously Unobserved Response Is Obtained During Testingp. 241
Documenting a Disaster Investigationp. 242
Specificity Check in Drug Product Analysis Methodsp. 242
Product Stability Issues Associated with Leachablesp. 244
Referencesp. 245
Submissionp. 249
General Discussionp. 249
Dossier Format: The Common Technical Documentp. 250
Contents of the CTD Sections Relevant to Container Closure Systems and Their Safety Assessmentp. 252
Section 3.2.P.7, Descriptionp. 252
Section 3.2.P.2.4, Suitabilityp. 254
Closing Observationsp. 262
Referencesp. 263
Launchp. 265
Product Maintenancep. 271
Product Maintenancep. 273
General Discussionp. 273
Ongoing Quality Controlp. 275
Generalp. 275
Incoming Raw Materialsp. 275
Manufactured In-Process Goodsp. 278
Finished Goods (Final Product)p. 279
Process of Developing-Implementing QC Extractables Specificationsp. 281
Change Controlp. 282
Generalp. 282
Change Control Impact Assessmentp. 285
Evaluation Recommendationp. 295
Factors to Consider When Contemplating Changes to Registered Productsp. 296
Case Study: Differential Approachp. 297
Overviewp. 297
General Test Strategyp. 297
Experimentalp. 298
Results and Discussionp. 299
Principles for Judging Toxicological Equivalencyp. 304
Disaster Management During Product Maintenancep. 305
A typical Manufacturing During Product Maintenancep. 305
Product Use Field Issues Encountered During Product Maintenancep. 309
Changes in Product Registration Requirements During Product Maintenancep. 312
Exiting the Product Maintenance Stagep. 313
Referencesp. 313
Retirementp. 315
Focus on Emerging Conceptsp. 319
Overviewp. 319
Plastic Materials used in Manufacturing Applicationsp. 320
Generalp. 320
Regulatory Requirementsp. 321
Industry Recommendationsp. 322
Case Study: Leachables Evaluation for Bulk Drug Substancep. 326
Process for Performing Extractables and Leachables Assessments for Disposable Materials Used in Bioprocessingp. 327
A Matter of Semanticsp. 328
Best Demonstrated Practices in Extractables Assessmentsp. 331
The Broader Context of Suitability for Usep. 337
An Important Practical Considerationp. 340
Future Considerationsp. 342
Referencesp. 344
Appendix: Materials Used in Pharmaceutical Constructs and Their Associated Extractablesp. 347
Referencesp. 370
Indexp. 371
Table of Contents provided by Ingram. All Rights Reserved.

Supplemental Materials

What is included with this book?

The New copy of this book will include any supplemental materials advertised. Please check the title of the book to determine if it should include any access cards, study guides, lab manuals, CDs, etc.

The Used, Rental and eBook copies of this book are not guaranteed to include any supplemental materials. Typically, only the book itself is included. This is true even if the title states it includes any access cards, study guides, lab manuals, CDs, etc.

Rewards Program